Dreem 3S

The Dreem 3S is a prescription Electroencephalograph (EEG) designed to measure and analyze brain electrical activity for sleep assessment in adults, utilizing a sophisticated machine learning model integrated with accelerometer data. Its novel Predetermined Change Control Plan allows for iterative algorithmic enhancements while ensuring sustained clinical performance and adherence to regulatory standards.

The Dreem 3S, a prescription Electroencephalograph (EEG) device, received substantial equivalence for its use in measuring, recording, displaying, transmitting, and analyzing brain electrical activity to assess sleep in adults aged 22-65 years. Usable in both home and healthcare settings, it generates hypnograms and summary sleep metrics from integrated EEG and accelerometer data.A significant aspect of its clearance is the Predetermined Change Control Plan (PCCP), which permits future algorithmic updates—covering signal preprocessing, machine learning models, and probability postprocessing—aimed at improving sleep staging performance without requiring new regulatory submissions. These changes necessitate comprehensive software verification and validation to ensure non-inferior clinical performance, alongside adherence to ongoing general regulatory controls.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How do the Dreem 3S's machine learning algorithms for sleep staging compare in accuracy and precision to manual scoring or other automated systems across different sleep disorders?; What specific validation studies and performance benchmarks will be used to demonstrate "non-inferior clinical performance" for algorithmic updates under the Predetermined Change Control Plan?; Are there plans to expand the device's indications for use beyond adults aged 22-65, such as for pediatric populations or specific neurological conditions, and what would that entail?; How does the data quality and reliability of EEG and accelerometer measurements from the Dreem 3S vary between home and professional healthcare environments?; What long-term data collection or post-market surveillance mechanisms are in place to monitor the real-world performance and impact of algorithmic changes?